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Abstract
Polycystic ovary syndrome (PCOS) is a common gynaecological disorder, with a prevalence of up to 12% of women of reproductive
age, and is in part characterised by elevated circulating androgens and aberrant expression of androgen receptor (AR) in the endome-
trium. A high percentage of PCOS patients suffer from infertility, a condition that appears to be linked to mistimed and incomplete
decidualisation critically affecting events surrounding embryo implantation. The aim of this study was to examine the involvement of
MAGEA11, and the genome-wide role of AR in PCOS.We determined that elevated androgen levels on PCOS cells had an impact on
the delayed and incomplete decidual transformation of endometrial cells. The AR co-regulator MAGEA11, a known enhancer of AR
function, was constitutively overexpressed throughout the menstrual cycle of PCOS patients, co-localised in the nucleus of PCOS
stromal tissue and cells and formed amolecular complex with AR. Genome-wide AR analysis in PCOS stromal cells revealed that AR
targets included genes involved in cell death and apoptosis, as well as genes commonly dysregulated in endometrial cancer. Enhanced
MAGEA11 and AR-mediated transcriptional regulation may impact on a correct endometrial decidualisation response, subsequently
affecting endometrial receptivity in these infertile women.
Key messages
& MAGEA11 and AR are overexpressed in hyperandrogenic PCOS patients.
& MAGEA11-AR overexpression in PCOS correlates with delayed decidualisation.
& AR and MAGEA11 associate in a molecular complex.
& AR directly regulates a unique set of genes controlling gene differentiation.
Keywords PCOS . AR .MAGEA11 . Decidualisation . Delay
Introduction
Polycystic ovary syndrome (PCOS) is a common
gynaecological disorder affecting 4–12% of reproductive age
women. Up to 44% of unexplained infertility cases display a
PCOS morphology linked with ovulatory dysfunction and
systemic hyperandrogenaemia. PCOS patients accumulate an-
drogens due to defects in aromatase activity that prevents the
conversion of androgens to oestrogens [1]. Despite ovulation,
a proportion of PCOS patients remain infertile suggesting an
important role for endometrial receptivity, orchestrated by em-
bryo implantation and decidualisation, a phenomenon that in-
volves dramatic morphological and functional differentiation
of human endometrial stromal cells (hESCs) [2, 3]. In addi-
tion, endometrial cells from women treated with androgens
exhibit altered growth and differentiation in vitro suggesting
a potential decidualisation defect in PCOS patients [4].
Previously, we have shown that levels of apoptosis are re-
duced in stromal cells in both ovulatory PCOS and androgen-
treated fertile samples [4]. This is accompanied by increased
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levels of anti-apoptotic factors Bcl2 and p27, and dramatic re-
ductions in EGFR andWT1 expression in response to androgens
[4]. Such alterations may contribute to the dysregulation of dif-
ferentiation and cell cycle, thereby compromising the reproduc-
tive potential of PCOS patients [4].
The effects of androgens are mediated through androgen
receptors (AR), nuclear hormone receptors that bind to and
regulate the expression of specific target genes. AR functions
through interactions with co-regulator proteins that result in
the repression or activation of target gene transcription
through modification of chromatin structure and regulation
of RNA polymerase activity [5]. AR co-regulator proteins
include MAGEA11, which has been shown to physically as-
sociate with the nuclear receptor in vitro [6, 7]. MAGEA fam-
ily members are involved in the regulation of apoptosis, cell
cycle progression, cellular differentiation, and proliferation
[8–10]. Endometrial MAGEA11 expression has been shown
in the secretory phase of the menstrual cycle in fertile women
[11]. In vitro experiments demonstrated a progesterone recep-
tor (PR) isoform B specific requirement for MAGEA11 in the
activation of progesterone-regulated genes [7]. In prostate
cancer, MAGEA11 is an androgen responsive gene and, fol-
lowing exposure of cells to androgens, co-localises to the nu-
cleus with AR, where it functions as an AR co-regulator in-
creasing AR transcriptional activity [12].
Here, we show that the addition of androgens disrupts the
differentiation of endometrial stromal cells during the process
of decidualisation in vitro. This process is accompanied by
increases in the expression of MAGEA11, which is recapitu-
lated in the endometrium of PCOS patients. Following treat-
ment with dihydrotestosterone (DHT), both MAGEA11 and
AR accumulate and co-localise in the nucleus both in vitro and
in vivo in endometrial tissues obtained from PCOS patients.
Genome-wide analysis of AR interactions using chromatin
immunoprecipitation revealed that AR interacts with genes
involved in the regulation of cell death and apoptosis includ-
ing EGFR and WT1, supporting the notion that elevated an-
drogens result in delayed decidualisation processes, and im-
plicating AR and MAGEA11 in incorrect endometrial differ-
entiation. This could impact on the critical timing process of
embryo implantation, and thus human reproduction.
Materials and methods
Stromal cell isolation
Primary endometrial stromal cells (ESCs) were isolated from
endometrial biopsies as previously described [4], yielding a ~
95% pure stromal cell culture [13]. ESCs (6 × 105 cells) were
cultured in 6-well plates for 24 h prior to treatments. Confluent
ESC monolayers were treated with cAMP (500 μM, A6885,
Sigma, UK), DHT (10−8 M, A8380, Sigma), and DHT +
cAMP (10−8 M + 500 μM) for 24 h, 48 h, and 72 h. RNA
was extracted after treatments and cell morphology assessed
throughout the duration of the experiment.
Morphological analysis
Primary cells were washed in PBS and fixed for 15 min in 4%
paraformaldehyde buffered in 0.1 M sodium cacodylate
(pH 7.2). Standard light microscope images (Zeiss Axiovert™,
UK)were captured and shape indexwas used to calculate chang-
es in cell shape. ImageJ software was used to calculate the cir-
cularity of the cells and this was performed as previously de-
scribed [14]. A perfect circle (indicating a decidualised cell) has
a shape index of one while a straight line (indicating a non-
decidualised stromal cell) has a shape index of zero.
Enzyme-linked immune-sorbent assays
Human prolactin/IGFBP-1 DuoSet ELISA kits (DY682/
DY871, R&D Systems, MN, USA) were used to analyse the
presence of prolactin/IGFBP-1 in cell culture media. The tar-
get medium was collected from confluent monolayers of ESC
cells treated for 48 h with cAMP and DHT. The protocols
were performed as per manufacturer’s instructions and each
sample was measured in triplicates.
Patient samples
Patient recruitment and consent was carried out at the gynae-
cology clinics at Singleton Hospital, Swansea. Endometrial
biopsies from women in a natural menstrual cycle were ob-
tained for immunohistochemistry and in vitro studies. Patients
had not received exogenous hormonal therapy at least
two months before the procedure. Women with systemic dis-
eases, sexually transmitted infections, or evidence of endome-
tritis, endometrial hyperplasia, or endometrial polyp were ex-
cluded. The presence of chronic endometritis was ruled out by
immunohistochemical analysis of biopsy samples. The phase
of the natural menstrual cycle was confirmed by ultrasound
and histological criteria; urinary luteinising hormone (LH)
was used to document ovulation. The control group included
women with proven fertility and regular menstrual cycles. The
study group consisted of infertile women with PCOS; patients
in control and study groups were matched with regard to body
mass index (BMI) and smoking habits. PCOS was diagnosed
based on the Rotterdam criteria of ultrasound and clinical and
biochemical features of hyperandrogenism [15]. Anovulatory
PCOS patients were oligomenorrhoeic or amenorrhoeic, and
biochemical and clinical examinations confirmed the lack of
ovulation. The ovulatory PCOS patients had confirmed poly-
cystic ovaries on ultrasound, hyperandrogenism, and ovulated
spontaneously with serum progesterone levels measured at
LH + seven at least 30 nm/l, were nulliparous despite regular
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ovulatory cycles in the presence of patent tubes, and sperm
parameters were normal. Blood samples were collected from
patients at day two of the menstrual cycle for assessment of
hormone levels using the electrochemiluminescence immuno-
assays (Elecsys® assays and Elecsys® 2010 immunoassay
analyser, Roche) for progesterone, follicle stimulating hor-
mone (FSH), luteinising hormone (LH), and testosterone, as
well as radio-immunoassays (RIA, BeckmanCoulter), to mea-
sure androstenedione. Endometrial biopsies were obtained by
Pipelle endometrial sampling or by curettage concurrent to
diagnostic laparoscopy; samples were divided in two
groups for immunohistochemistry and in vitro studies.
A total of 116 patients were enrolled in the study, 51
of proven fertility and 65 infertile. Endometrial samples
were obtained from 58 patients in the secretory phase
[fertile (n = 33), infertile ovulatory PCOS (ovPCOS, n =
25)] and 37 patients in the proliferative phase. [fertile
(n = 18), infertile ovPCOS (n = 19)]. Endometrial sam-
ples were also taken from 21 PCOS women who were
anovulatory (anovPCOS). There were no statistically
significant differences in the mean age or body mass
index between the groups (Table 1). Both PCOS groups
exhibited statistically higher levels of serum testosterone
compared with the fertile group (Table 1).
Immunohistochemistry
Preparation of formalin-fixed paraffin-embedded (FFPE)
samples, nuclei-staining, and immunohistochemistry was per-
formed as previously described [16]. Positive (tonsil) and neg-
ative (endometrium) tissue sections were used as controls.
Rabbit polyclonal antibodies for anti-MAGEA11 (T1241,
Epitomics®, California, USA) and for anti-AR (N-20, Santa
Cruz®, California, USA) were used (1/50). Slides were eval-
uated using the H-scoring system by three independent scorers
blinded to patient diagnosis, demographics, and timing of bi-
opsy [16].
RNA isolation and qRT-PCR
RNA isolation, quantification, and qRT-PCR analysis using
gene-specific primer-pairs (available on request) were per-
formed as previously described [4]. Expression levels were
normalised to an internal reference gene (GAPDH).
Expression was calculated as a ratio between treated and con-
trol samples for each gene. Densitometry analyses were per-
formed using Image Lab software (BioRad, UK).
Immunofluorescence confocal microscopy
ESCs (2 × 105 cells) were grown to 80% confluence on 8-well
chambered borosilicate coverglass (Thermo Scientific Ltd.,
UK). At 24 h post induction of decidualisation (+DHT), cells
were fixed with 4% paraformaldehyde, permeabilised with
0.1% Triton X-100 (Sigma), and blocked with 3% BSA in
PBS for 1 h. Primary antibodies, anti-AR (ab9474,
Abcam®, Massachusetts, USA), and anti-MAGEA11
(ab60043, Abcam®) diluted in 3% BSA PBS were incubated
overnight at 4 °C, followed by 1 h incubation with secondary
antibodies, Alexa488 (green, mouse anti-AR) and Alexa
TexasRed (red, rabbit anti-MAGEA11). Cells were washed
with PBS extensively between all steps, counterstained before
imaging with NucBlue reagent (Life Technologies) and im-
aged using an LSM710 confocal fluorescence microscopy
system (Zeiss, UK).
Protein blotting and co-immunoprecipitation
Protein blotting was performed as previously described [14].
For co-immunoprecipitation, PCOS stromal cells were grown
to confluency and subsequently exposed to 0.1 μM DHT for
24 h before cells were fixed with 4% paraformaldehyde in
order to stabilise protein complexes. Total protein was extract-
ed using RIPA buffer and pre-cleared by rotation with A/G
PLUS-Agarose beads (sc-2003, Santa Cruz). The lysate was
subjected to anti-AR antibody (ab9474, mouse monoclonal)
Table 1 Patient demographics
Fertile (n = 51) Ovulatory PCOS (n = 44) Anovulatory PCOS (n = 21)
Age 30 ± 4.6 29.0 ± 5.0 (p = 0.728) 29.1 ± 2.6 (p = 0.562)
Body mass index (BMI, kg/m2) 26.8 ± 4.9 29.1 ± 5.0 (p = 0.520) 32.3 ± 5.8 (p = 0.076)
Progesterone (ng/mL) 31 ± 5.28 27.45 ± 11.5 (p = 0.597) N/A
FSH1 (mUI/mL) 7.4 ± 3.017 5.67 ± 1.37 (p = 0.135) 5.34 ± 2.57 (p = 0.2041)
LH2 (mUI/mL) 4.90 ± 2.221 12.70 ± 4.27 (p = 0.0004) 15.63 ± 4.94 (p = 0.0008)
Total testosterone (nmol/L) 0.76 ± 0.472 1.72 ± 0.313 (p = 0.1) 2.94 ± 0.108 (p = 0.001)
Free testosterone (nmol/L) 13.13 ± 6.12 18.5 ± 5.7 (p = 0.08) 37.15 ± 10.6 (p = 0.002)
Androstenedione (nmol/L) 3.43 ± 0.23 7.70 ± 1.6 (p = 0.006) 8.72 ± 1.1 (p = 0.0001)
1FSH follicle stimulating hormone
2 LH luteinising hormone
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O/N incubation (4 °C), followed by another incubation with
A/G PLUS-Agarose beads (2 h). After several washing steps,
the samples were separated by SDS-PAGE and probed using
an anti-MAGEA11 antibody (T1241, rabbit polyclonal).
Chromatin immunoprecipitation and DNA sequencing
PCOS ESCs (1.2 × 106 cells) were cultured in 75-cm2 flasks
for 24 h prior to DHT treatment (48 h). DHT-treated PCOS
ESC cells were then fixed using 1% formaldehyde solution
(Sigma®), quenched with 2.5 M Glycine (Sigma®), and cen-
trifuged following Active Motif’s Epigenetic Services ChIP
Cell Fixation Protocol instructions. The resulting pellet was
sent to Active Motif® for sequencing, alongside with an anti-
AR antibody (ab9474), which was used to probe for AR-target
region enrichment. Raw ChIP-seq data is deposited in the
GEO Dataset, with accession number GSE119432.
MEME-Suite
FASTA data files obtained from the AR ChIP-seq performed
on PCOS tissue were loaded onto the MEME-Suite. First, the
sequence analysis tool DREME (Bailey 2011) was used to
discover relatively enriched motifs, comparing the AR ChIP-
seq sequences with control shuffle sequences. Next, the motif
comparison tool Tomtom (Gupta et al. 2007) was used to
compare the DREME-enriched motifs against a database of
knownmotifs, providing a list of matches and their correspon-
dent p values.
Analysis of the ChIP-seq data and Venn diagram
Alongside with the correspondent FASTA files, Active
Motif® provided a list of 2798 genes. In most cases, the gene
sequence encompassed the associated ChIP-seq peak location,
although some upstream or downstream peaks were linked to
gene targets through the identification of nearby promoters.
Each gene was associated with a peak value, an average of
peak values in case the gene contains several peaks, which
were filtered to obtain a list of 577 high-intensity peaks (peak
value > 20). The list of 577 high-intensity peaks was com-
pared with a list of AR binding sites in human prostate cancer
tissues (Sharma et al. 2013) using a Venn diagram (Hulsen
et al. 2008).
Genomic Regions Enrichment of Annotations Tool
The filtered genomic localisation of 6296 AR-PCOS peaks
(peak value >20) was loaded onto Genomic Regions
Enrichment of Annotations Tool (GREAT) (McLean et al.
2010) in order to analyse the functional significance of
ChIP-seq-identified cis-regulatory regions (gene ontology).
Statistical analyses
Data distributions were assessed for normality using the
Kolmogorov Smirnov test. Non-normally distributed data
was analysed with the Mann-Whitney U test applied in a post
hoc to determine statistical significance. For normally distrib-
uted data, an ANOVA test followed by a t test was used to
determine significant differences between groups. The test
statistic and corresponding p value were reported. All data
analyses were performed using SPSS version 13.0 (SPSS,
Illinois, USA).
Results
Mesenchymal to epithelial transition is blocked
in PCOS stromal cells
Decidual transformation involves a mesenchymal to epithelial
(MET)-like phenotypic transition in hESC in response to cy-
clic AMP (cAMP) in a normal menstrual cycle [17]. We
assessed hESC isolated from primary tissue samples for a
decidual response by calculating the cell shape index for
MET. Cell shape index is a dimensionless quantitative mea-
sure of cell morphology acquired from standard light micro-
scope images [18]. Following an initial exposure to cAMP to
trigger differentiation, stromal cells underwent a rapid MET
transition, morphologically transitioning from elongated to
rounded cells with the calculated shape index approaching
one (Fig. 1a and Supplementary Fig. 1). The MET-like re-
sponse was initiated within the first 24 h following cAMP
treatment and was sustained over the duration of the experi-
ment, demonstrating that cAMP could effectively stimulate
the transition. This observed MET-like effect was not im-
paired when fertile cells were simultaneously treated with
cAMP and DHT, demonstrating that MET in fertile cells is
unaffected by DHT. In contrast, cells derived from PCOS
biopsies exhibited a delayed and only partial shape transition
(Fig. 1b). After 24 h the shape index was 0.3, and increased
slowly up to a maximum of 0.5 after 72 h in response to
cAMP. When cAMP and DHT were used in combination in
PCOS cells, the extent of the MET-like response remained
partial, with a shape index of 0.3 at each time points (Fig. 1b).
Prolactin and IGFBP-1 are known indicators of MET
in the context of hESC [17]; accordingly, the expression
of these markers was quantified using enzyme-linked im-
mune-sorbent assays (ELISA) (Fig. 1c, d). In fertile cells,
prolactin and IGFBP-1 levels were significantly in-
creased following exposure to cAMP (prolactin:
p < 0.01; IGFBP-1: p = 0.025) and cAMP + DHT (prolac-
tin: p = 0.03; IGFBP-1: p < 0.01). In accordance with the
morphological response observed in PCOS patients (Fig.
1b), PCOS cells exhibited a limited upregulation of
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prolactin and IGFBP-1 following exposure to cAMP
(prolactin: p < 0.01; IGFBP-1: p = 0.035) and cAMP +
DHT (prolactin: p = 0.03; IGFBP-1: p = 0.02). These
results are consistent with previous observations and in-
dicate that the decidual response is either delayed or
inhibited in PCOS patients.
Fig. 1 Regulation of MAGEA11 expression in ESC during in vitro
decidualisation. Endometrial stromal cells (ESC) isolated from biopsies
of fertile (n = 8) and PCOS (n = 9) patients were left untreated (C), incu-
bated with cyclic AMP (cAMP, 0.5 mM), dihydrotestosterone (DHT,
10−6 M) or a combination of both for 24 to 72 h. ESCs were obtained
from cells in the secretory phase of the cycle. Cell morphology was
recorded throughout the experiment to document decidual changes. a, b
ESC shape changes were assessed as described in the “Materials and
Methods” section. ImageJ software was used to calculate the circularity
of the cells (n = 20/group), with a perfect circle having a value of one,
while a straight line has a circularity value of zero. c, d Cell media was
extracted after ESCs were isolated and treated for 48 h. ELISA experi-
ments were carried out on the conditioned media to establish the concen-
tration of key proteins (prolactin/IGFBP-1) at the secreted level. Values
were compared with their corresponding untreated cells. e, f After incu-
bation, cell pellets were collected and RNA extracted to analyse
MAGEA11 transcript levels by qRT-PCR. All values represent the aver-
age and standard deviation. Statistical analysis of the data was performed
between samples of the same clinical sub-group using an ANOVA test
followed by a t test (treated vs untreated). *p ≤ 0.05 and **p ≤ 0.01 were
considered significant
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In vitro response to DHT and cAMP treatments
Steroids (DHT) and second messengers (cAMP) regulate the
expression of the AR co-regulator MAGEA11 in human en-
dometrial cell lines [11]. Accordingly, treatment of hESCs
isolated from fertile samples with cAMP triggered a rapid
and short-lived induction of MAGEA11 expression after
24 h (fold change = 1.9, p < 0.01), which decreased after
48 h and 72 h (Fig. 1e). For PCOS cells, the opposite response
was observed, with MAGEA11 upregulation delayed until
72 h (fold change = 1.88; p < 0.01) (Fig. 1f). This delayed
expression of MAGEA11 is consistent with previous obser-
vations, as the timing of maximal MAGEA11 mRNA expres-
sion in fertile women coincides with the window of receptivity
to embryo implantation in the mid-secretory phase of the men-
strual cycle [11], and thus suggests an anomalous decidual
response in PCOS patients.
Cells were then treated with DHT, and in fertile hESC,
MAGEA11 expression was significantly reduced at all time
points (24 h: fold change = 0.23, p < 0.01; 48 h: fold change =
0.24, p < 0.01; 72 h: fold change = 0.48, p < 0.01), and when
used in combination with cAMP, was further reduced after 48
and 72 h (48 h: fold change = 0.54, p < 0.01; 72 h: fold
change = 0.21, p < 0.01) (Fig. 1e). This suggests that DHT
through the action of AR, which is expressed at low levels
in the mid-secretory phase of the menstrual cycle [11], re-
presses normal MAGEA11 expression. In contrast, in PCOS
samples, there was a dramatic increase in MAGEA11 expres-
sion 72 h post-treatment (DHT: fold change = 7.03, p = 0.01;
cAMP +DHT: fold change = 4.05, p = 0.03, Fig. 1f) indicat-
ing that MAGEA11 is positively regulated by DHT in PCOS
stromal cells.
Expression of MAGEA11 and AR in proliferative
and secretory phase endometrial biopsies
To determine whether the expression of MAGEA11 in vivo
was similar to that observed in vitro, biopsies obtained from
proliferative endometrium of fertile and PCOS patients were
assessed using immunohistochemistry (IHC).
Fig. 3 MAGEA11 expression in secretory phase endometrium. Secretory
phase endometrium from fertile (n = 33) and ovulatory PCOS (ovPCOS,
n = 19) patients was analysed for the expression of MAGEA11/AR as
de s c r i b ed i n t he “Mate r i a l s and Me thod s ” s e c t i on . a
Inmunohistochemistry (IHC) figures showing MAGEA11/AR expres-
sion; IHC images display × 10 magnification. Scale = 50 μm. b, d
Analysis of the IHC scores (H-score) for MAGEA11 and AR antibodies.
Fertile (n = 33); ovPCOS (n = 19); E, epithelial; S, stromal. c, e RNA
samples obtained from endometrial biopsies were analysed for the ex-
pression of MAGEA11/AR transcript levels as described in the
“Materials and Methods” section. Fertile (n = 12); ovPCOS (n = 8). All
values represent the median and inter-quartile range (box and whisker).
Statistical analysis was performed using the Mann-Whitney U test. *p ≤
0.05 and **p ≤ 0.01 are considered significant
Fig. 2 MAGEA11 expression in proliferative phase endometrium.
Proliferative phase endometrium from fertile, anovulatory PCOS and
ovulatory PCOS patients was analysed for the expression of
MAGEA11/AR as described in the “Materials and Methods” section. a
Immunohistochemistry (IHC) figures showing MAGEA11/AR expres-
sion; IHC images display × 10 magnification. Scale = 50 μm. b, d
Analysis of the IHC scores (H-score) for MAGEA11 and AR antibodies.
Fertile (n = 18); anovulatory PCOS (anovPCOS, n = 21); ovulatory
PCOS (ovPCOS, n = 25); E, epithelial; S, stromal. c, e RNA samples
obtained from endometrial biopsies were analysed for the expression of
MAGEA11/AR transcript levels as described in the “Materials and
Methods” section. Fertile (n = 10); anovPCOS [12]; ovPCOS (n = 6).
All values represent median and inter-quartile ranges (box and whisker).
Statistical analyses were performed using theMann-WhitneyU test. *p ≤
0.05 and **p ≤ 0.01 were considered significant
J Mol Med
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MAGEA11 was present in epithelial and stromal compart-
ments of fertile endometrium, with expression restricted to the
cytoplasm (Fig. 2a, b and Supplementary Fig. 2), and only low
levels of MAGEA11 mRNA were detected in whole tissue
extracts (Fig. 2c). Secretory phase expression was significant-
ly higher in epithelial (p = 0.03) and stromal tissue (p < 0.01)
compared with proliferative phase samples in fertile samples
(Fig. 3a, b and Supplementary Fig. 2), confirming that
MAGE11 expression is increased around the window of im-
plantation [11]. Similarly, MAGEA11 mRNA expression
showed an almost 3-fold increase in the secretory phase com-
pared the proliferative phase in whole tissue samples (Fig. 3c,
p = 0.01).
In ovulatory (ovPCOS) and anovulatory PCOS
(anovPCOS), MAGEA11 levels were significantly higher
than in fertile patients (Figs. 2 and 3 and Supplementary Fig.
2). Proliferative phase ovPCOS epithelial (p < 0.01) and stro-
mal (p < 0.01) compartments showed high levels of expres-
sion, which were further increased in the secretory phase (ep-
ithelial and stromal p < 0.01). Similarly, MAGEA11 levels
were significantly elevated in anovPCOS samples in both
the epithelial (p < 0.01) and stromal (p < 0.01) compartments
(Fig. 2a, b and Supplementary Fig. 2). MAGEA11 mRNA
expression levels were significantly elevated in both
ovPCOS (proliferative, p = 0.01; secretory p = 0.05) and
anovPCOS (p = 0.0011) compared with fertile sample levels
(Figs. 2c and 3c).
AR staining in fertile endometrium was higher during the
proliferative phase of the cycle and predominantly expressed
within the stromal compartment (Figs. 2d and 3d). Consistent
with other studies [19, 20], this suggests that in fertile endo-
metrium, an increase in MAGEA11 is unlikely to be due to
AR activity, as the two molecules are expressed in different
phases of the menstrual cycle. In PCOS samples, AR staining
(Figs. 2d and 3d) was higher compared with the fertile sam-
ples, andMAGEA11 and AR expression occurred concurrent-
ly throughout the cycle (Figs. 2e and 3e).
MAGEA11 co-localises with AR in the nuclei of PCOS
stromal cells
Detailed analysis of AR andMAGEA11 distribution in PCOS
samples revealed that they accumulate at high levels in both
cytoplasmic and nuclear compartments (Figs. 2 and 3), where-
as in cells from fertile patients, only low levels of AR and
MAGEA11 staining were seen, andMAGEA11was restricted
to the cytoplasm. PCOS-specific nuclear co-localisation was
also observed in vitro by confocal immunofluorescence mi-
croscopy when hESCs isolated from PCOS patients were
treated with DHT (Fig. 4a and Supplementary Fig. 3). It ap-
pears that the two proteins could interact prior to nuclear im-
portation, as per observed perinuclear or membrane-
associated co-localisation (Fig. 4a and Supplementary Fig. 3).
Having demonstrated the temporal and spatial co-location
of the two proteins, their direct molecular interaction was
assessed, as such an interaction would support the notion that
MAGEA11 functions as an AR nuclear co-regulator in the
endometrial stroma, similar to its function in prostate cancer
cells. Fertile and PCOS primary stromal cells were grown to
confluence, and total protein extracted. Protein blot analysis
revealed a major 50-kDa MAGEA11 isoform, corresponding
to the canonical isoform one of the protein, which was
expressed in both cell types (Fig. 4b). The bands observed in
the 20–37-kDa range could be a result of cross-reactivity with
other MAGEA11 isoforms, as well as with a number of highly
homologous MAGE proteins (e.g., MAGEA4, 34.7 kDa)
[21]. Densitometry analysis demonstrated that canonical
MAGEA11 expression was significantly greater in PCOS
samples confirming IHC and cytometric analysis (Fig. 4b).
Subsequently, the co-immunoprecipitation analysis was car-
ried out in order to demonstrate any direct molecular interac-
tion between MAGEA11 and AR. In PCOS stromal cells
treated with 0.1 μM DHT full-length ~ 50 kDa isoform one,
MAGEA11 was detected at levels significantly above back-
ground (IgG), whereas no increase was observed in untreated
cells (Fig. 4c). A second band (~ 25 kDa) was detected as a
result of co-immunoprecipitation (Fig. 4c), likely a product of
the degradation of MAGEA11, which is known to have a
short half-life [22]. These data demonstrate an association
between native AR and MAGEA11 isolated from primary
endometrial stromal cells, and given previous studies have
shown that the MAGEA11-AR interaction has an absolute
requirement for DHT, this suggests that such a complex would
only form in PCOS patients with hyperandrogenaemia.
Characterisation of AR targets in PCOS
AR expression in PCOS stromal cells is likely to drive
transcriptional re-programming and, as such, has a direct
role in the delay of endometrial cell differentiation (Figs.
2 and 3). We therefore conducted genome-wide
localisation experiments using chromatin immunoprecipi-
tation coupled with DNA sequencing (ChIP-seq) to under-
stand which transcriptional networks were likely to be
regulated by AR. ChIP-seq chromatin isolated from
DHT-treated PCOS hESCs probed with an anti-AR anti-
body identified 6296 loci (FDR 0.06%) that were enriched
for AR, with no Y chromosome representation (Table 2;
Supplementary Table 1). The majority of AR binding oc-
curred distal to the transcription start site, at distances
between − 500 and − 50 kb (Fig. 5a). To confirm the va-
lidity of the AR targets identified, we tested for the pres-
ence of consensus AR binding sites (RAACR) using the
MEME software [24] and demonstrated that the nuclear
receptor specifically recognised its cognate binding se-
quence (p = 3.85E− 05) (Fig. 5b). In addition, AR also
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displayed highly specific recognition for JUN binding
sites (p = 1.725E− 07, RTGAVTCA) and Sp1 (data not
shown). JUN proteins are components of the AP-1 tran-
scription activator family that have previously been
shown to interact with, and enhance AR activity in pros-
tate and prostate cancer cells [25, 26].
Gene ontology analysis revealed that AR targets were pre-
dominantly involved in processes related to the positive reg-
ulation of cell death, including apoptosis (Supplementary
Table 2). This finding supports our early observations show-
ing that apoptosis is delayed in PCOS, and suggests that the
overexpression and hyperactivation of ARmay be responsible
for this. In addition, a number of specific AR targets including
KLF9, KLF13, and PLZF were identified, all of which have
roles in decidualisation [27, 28].
As AR functions predominately in male reproductive tissue,
we asked whether the endometrial AR targets and regulatory
pathways identified through our ChIP-seq analysis were tissue
and gender-specific. Comparison of endometrial AR targets
(577 genes) with AR targets from a prostate-specific data set
(1371 genes) [23] revealed a set of targets that were specific to
endometrial tissue (501 genes, Table 2), as well as a set of
common AR targets (76 genes, Table 2). Common PCOS-
prostate targets include a number of genes involved in well-
Fig. 4 MAGEA11 protein
localises to the nucleus of
endometrial stromal cells and
interacts with AR in PCOS
patients. a Immunofluorescence
confocal microscopy images of
fertile and PCOS hESCs that were
either left untreated (control, left
panel) or treated with DHT for
48 h (DHT, right panel). ESCs
were obtained from cells in the
secretory phase of the cycle.
Fixed cells were incubated with
anti-AR and anti-MAGEA11 an-
tibodies for detection. Scale =
20 μm. b Cell lysates from fertile
(n = 3) and PCOS (n = 3) ESCs
were subjected to western blot
analysis. The left panel shows a
representative blot of MAGEA11
protein expression and the right
panel displays the corresponding
densitometry; values were nor-
malised to GAPDH expression
and are expressed as average and
standard deviation (SD). The sta-
tistical analysis was performed
using Student’s t test; *p ≤ 0.05 is
considered significant. c Cell ly-
sates from PCOS ESCs were ei-
ther left untreated (control, left
panel) or treated with DHT for
24 h (right panel) and subjected to
protein co-immuneprecipitation
using an anti-AR antibody
(N-20). Input was used as positive
control and IgG as a negative
control
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known carcinogenic processes such as Rho-GTPase signalling
(ROCK1) [29] or the NF-κβ pathways (PYGB) [30], mecha-
nisms commonly associated with the regulation of apoptosis.
These findings indicate that AR targets are predominantly gen-
der specific, although there is an overlap that highlights the
connection between male and female reproductive
malignancies.
Finally, as PCOS patients have an increased risk of devel-
oping endometrial cancer (EC), we considered whether any
AR targets were implicated in this disease. Comparison of our
data with a list of EC-related genes obtained from PubMed
databases revealed a set of known oncogenic targets (16
genes, Fig. 5d), including tumour suppressor PTEN, whose
expression is commonly lost in endometrial cancer tissues
[31], the matrix metalloproteinase-2 (MMP2) and YAP1,
which are commonly found overexpressed in endometrial
cancers [32, 33]. Additionally, our comparisons identified
the tumour suppressor gene WT1, whose expression is down-
regulated in PCOS endometrium during implantation [4].
Discussion
The window of implantation during the female reproductive
cycle is a tightly controlled process, which if perturbed can
result in the inability of the endometrium to receive and
implant a blastocyst, and subsequently to establish the earliest
phase of pregnancy. PCOS is a common multi-factorial disor-
der linked to female infertility. In women with PCOS symp-
toms who continue to ovulate, loss of normal endometrial
function appears to be an underlying factor associated with
infertility. Incorrect decidualisation, including timing and in-
complete cellular transformation, can result in a non-receptive
endometrium and incorrect intercellular signalling between
the maternal tissue and the embryo.
A common feature of PCOS is elevated levels of circulating
androgens—hyperandrogenaemia. This coincides with increased
and temporally abnormal expression of the AR in endometrial
tissue, which could lead to the activation of AR-driven transcrip-
tional programmes. AR is a DNA-binding transcription factor,
the function of which is to recruit co-regulator proteins to target
genes resulting in either the activation or repression of the tran-
scription of these targets. MAGEA11 has been described as a co-
activator of AR in prostate tissues. Here, we show that the ex-
pression of MAGEA11 is increased in the endometrial stroma of
PCOS tissue and cells isolated from this stromal compartment
treated with DHT. This is a PCOS-specific effect, as MAGEA11
does not increase in the stromal component of endometrial tissue
from fertile controls, nor does DHT treatment of cells derived
from this tissue result in increased MAGEA11 expression.
MAGEA11 protein was present as the canonical 50 kDa isoform
one in PCOS stromal cells, where it interacted directly with AR
Table 2 Top androgen receptor targets in endometrial (PCOS) and castrate-resistant prostate cancer tissues
PCOS specific Common PCOS-CRPC (prostate)
Symbol Peak value Accession No. Symbol Peak value Accession No.
DUSP27 130 NM_001080426 HFM1 185 NM_001017975
MIR663 104 NR_030386 SLC25A44 153 NM_014655
LOC100505875 100 XR_112656 PMF1 153 NM_007221
LOC100506842 94 XR_112632 PDE3A 114 NM_000921
NFXL1 94 NM_152995 NLE1 109 NM_001014445
MEF2D 87 NM_005920 UNC45B 109 NM_173167
C14orf145 84 NM_152446 YEATS2 105 NM_018023
TAF8 82 NM_138572 ABCC5 68 NM_005688
ZRANB2 74 NM_005455 DNAJB12 54 NM_001002762
PPM1D 74 NM_003620 LRRFIP2 47 NM_017724
TRIM56 74 NM_030961 PYGB 45 NM_002862
LTBP4 70 NM_003573 GTDC1 44 NM_024659
ENTPD4 69 NM_004901 BATF 40 NM_006399
TOP 64 XR_109290 C6orf81 40 NM_145028
MIR1826 64 NR_031727 FAM105A 39 NM_019018
MMP19 63 NM_002429 BLK 38 NM_001715
RANBP3 63 NM_007322 RGS22 36 NM_015668
C19orf45 63 NM_198534 ROCK1 35 NM_005406
ZNF358 63 NM_018083 SOX13 34 NM_005686
MCOLN1 63 NM_020533 KLF9 33 NM_001206
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in the presence of DHT. This is the first time this AR-MAGEA11
interaction has been demonstrated with native proteins isolated
from primary endometrial cells and verifies that the AR-
MAGEA11 interaction previously shown using overexpressed
proteins isolated from mammalian expression systems is indeed
physiologically relevant.
AR chromatin immunoprecipitation experiments using
PCOS stromal cells stimulated with DHT identified the direct
targets of the nuclear hormone receptor. Krüppel-like factor
(KLF)-9 and 13 transcription factors (KLF9/KLF13) were both
major AR targets as determined by the depth of read. KLF9 is
expressed in endometrial stromal cells but controls the response
of adjacent luminal epithelial cells to progesterone [27]. In mu-
rine models, loss of klf9 results in less post-implantation em-
bryos, which appears to be due to increased levels of BMP2 in
these animals. In hESC treated with cAMP, estradiol-17β (E2)
and medroxyprogesterone acetate to induce decidualisation, as
well as siRNA to knock down KLF9 expression, both KLF13
and BMP2 mRNA levels increase. Conversely, in the same
decidualised hESC model, siRNA to knock down KLF13 re-
sults in the increase of KLF9 expression and reduction of
BMP2. This KLF-BMP appears important as the endometrial
stromal cells of bmp2-deleted mice are infertile [27]. Disruption
of this signalling axis by AR binding to KLF9 and 13 could
Fig. 5 Genome-wide analysis of AR targeting in PCOS stromal cells. a
Diagram showing the average distribution of AR binding sites
surrounding gene transcription starting sites (TSSs) in human PCOS tis-
sue. This diagram was generated using the Genomic Regions Enrichment
of Annotations Tool (GREAT). Blue columns represent the whole set of
filtered AR peaks and green columns represent AR peaks directly linked
to the PCOS disease, according to GREAT databases. b Sequence logos
and correspondent p values of transcription factor bindingmotifs enriched
for AR in human PCOS tissue, generated with the MEME-Suite applica-
tion. c Venn diagram showing the overlap between AR binding sites
identified in human PCOS tissue and castrate-resistant prostate cancer
(CRPC) [23]. d Table containing the list of genes identified as targets of
AR in PCOS tissue, which are also involved in endometrial cancer dis-
ease, according to the NCBI databases
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therefore be a cause of delayed/failed decidualisation in PCOS
patients. The promyelocytic leukaemia zinc finger transcription
factor (PLZF) was a second transcription factor identified as a
direct AR target. PLZF appears to have a role in P4-dependant
hESC decidualisation as it is normally induced by P4 and con-
tains PR regulator regions, and controls EGR1 expression
levels [28]. KLF9/13 and PLZF normally function through
the PR transcription pathway. It appears overexpression and
activation of AR could disrupt this normal high-level transcrip-
tional programming via driving misexpression of these key
transcriptional regulators in PCOS patients.
Interestingly, as well as binding to AR response elements, the
nuclear receptor is also recruited to JUN response element-
containing regulatory regions, presumably by a JUN response
element-binding protein such as c-Jun, which interacts directly
with AR in prostate cancer cells and enhances the trans-
activation function of AR [25, 26].
Gene ontology analysis of AR chromatin immunoprecipi-
tation data revealed that AR interacts with genes involved in
the regulation of cell death and apoptosis including EGFR and
WT1, the expression of which is reduced in PCOS [4], sug-
gesting AR may act as a repressor at the WT1 locus. The
consequences of this repression have been highlighted before
[4] and substantiate a functional role of AR in decidualisation.
Bcl2, a known WT1 target, becomes upregulated in PCOS
patients following AR activation, delaying the cell cycle and
inhibiting apoptosis via p27 [34]. β-catenin, repressed by
WT1 in fertile cells [35], is expressed in PCOS women, and
likely contributes to the abnormal upregulation of the Wnt
pathway [4, 36]. The impact of AR targeting these genes ap-
pears to be manifested in the delayed and incomplete morpho-
logical transition of stromal cells isolated from PCOS endo-
metrium where cells retain a more elongated mesenchymal-
like phenotype and produce a limited amount of prolactin
when treated with the decidualisation stimulus of cAMP.
Together, these data support the notion that elevated andro-
gens result in delayed decidualisation and implicate AR and its
co-regulator MAGEA11 in incorrect endometrial differentiation,
the critical timing process of embryo implantation, and thus hu-
man reproduction.
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